newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

  • Cogent Biosciences announced that Phase 3 PEAK trial results for bezuclastinib plus sunitinib in GIST patients will be presented orally at the 2026 ASCO Annual Meeting in Chicago.
  • The presentation covers data from a positive trial involving patients with Gastrointestinal Stromal Tumors who received prior imatinib treatment.
  • Top line results were reported in November 2025, & the New Drug Application was submitted under the Real-Time Oncology Review program in March 2026.
  • The abstract titled "Primary Results of the Phase 3 Peak Study of bezuclastinib + sunitinib vs sunitinib Monotherapy in Advanced Gastrointestinal Stromal Tumors (GIST)" is assigned Abstract Number 11500.
  • Presenter Andrew J. Wagner, M.D., Ph.D., will deliver the presentation during the "Oral Abstract Session - Sarcoma" on May 30, 2026.
  • The session takes place from 3:00 PM-6:00 PM CT at the McCormick Place Convention Center in Chicago, IL.
  • Cogent is on track to initiate a Phase 2 trial this quarter investigating bezuclastinib plus sunitinib for first-line GIST patients with exon 9 mutations.
  • Bezuclastinib is a selective tyrosine kinase inhibitor designed to inhibit KIT D816V mutations & other mutations in KIT exon 17 associated with systemic mastocytosis & advanced GIST.
  • The company is also developing novel targeted therapies for mutations in ErbB2, PI3Kα, KRAS, & JAK2.
  • Cogent Biosciences is headquartered in Waltham, MA, & Boulder, CO.